MYO MYOMO, INC.

CIK 0001369290 22 ready 8-Ks latest May 7, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 22

Latest filing May 13, 2026, 4:10 PM ET

Top materiality 0.85

Event mix earnings ×10 · other_material ×6 · leadership ×2

Sentiment 10 pos · 2 neg · 10 neu

Latest earnings ▲ beat 2026-Q1

Executive change recent →

Recent 8-K filings for MYO

Highest-materiality recent filing

Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M

August 11, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).
Orders/authorizations 207 (-3%), backlog 230 units (-18%), pipeline adds 816 (+49%).

Read filing →

May 7, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q1 revenue $10.1M (+3% YoY); net loss narrows to $3.0M; guides Q2 $10.3M-$10.8M

Revenue $10.1M (+3% YoY), net loss $3.0M ($0.07/sh) vs $3.5M loss ($0.08/sh) in Q1 2025.
March 9, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Myomo Q4 revenue falls 6% to $11.4M; net loss widens to $3.8M

Q4 revenue $11.4M (-6% YoY); full year $40.9M (+26% YoY).
November 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 1.01 item 2.02 item 2.03 item 3.02 item 9.01 ◈ Debt Financings

Myomo Q3 revenue $10.1M (+10% YoY); net loss $0.09/shr; FY guidance $40-42M

Revenue $10.1M, up 10% YoY; 186 units sold (+16%), ASP ~$54,200 (-5%).
August 11, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M

Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).
June 18, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Myomo sets 2028 revenue target of $100M, gross margin 70-72% at Investor Day

Aspirational goal of $100M annual revenue by 2028, including $15M international and $20M O&P channel revenue.
May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Myomo Q1 revenue $9.8M (+162%); record 700 pipeline adds; guides Q2 $9.0-9.5M

Revenue $9.8M (+162% YoY) on 182 units (+100%); gross margin 67.2% (up 600 bps).
April 10, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Myomo names CBIZ as new auditor; two directors exit board

Marcum LLP resigned as auditor April 8; CBIZ CPAs engaged after acquiring Marcum's attest business.
March 10, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Myomo Q4 revenue $12.1M record, first positive op. cash flow; guides FY2025 $50-53M

Q4 revenue $12.1M (+154% YoY); 220 units shipped (+106%); ASP ~$54,900 (+23%).
December 5, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Myomo prices $15M public offering of 3M shares at $5.00; underwriter option exercised in full

3,000,000 shares priced at $5.00 each; gross proceeds of $15.0M expected before expenses.
November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M

Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.
August 13, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 2.03 item 9.01

Myomo signs 88-month lease for 36,208 sq ft in Burlington, MA for HQ and manufacturing

Lease for approx. 36,208 rentable sq ft at 45 Blue Sky Drive; monthly rent starts at $96,250 and escalates over 8-year term.
August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders

Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.
July 15, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 2.03 item 9.01

Myomo enters $4M revolving credit facility with Silicon Valley Bank

Revolver up to $4M (expandable to $5.5M); interest rate greater of 8.50% or prime + 0.50%.
July 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Myomo expects record Q2 revenue $7.2M-$7.4M, up 92-97% sequentially

Preliminary Q2 revenue $7.2M-$7.4M, 92-97% sequential increase, highest ever.
May 8, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M

Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).
May 6, 2024, 7:59 PM ET regulatory materiality 0.65 positive item 8.01 item 9.01

Myomo receives first lump sum Medicare reimbursements for MyoPro under new CMS fees

CMS through DME MACs remitted lump sum reimbursements for MyoPros to Medicare Part B beneficiaries.

Executive changes

Appointed

Joseph M. Manko Jr.

Class I director

MYO · MYOMO, INC.

Effective: 2026-05-09
Filed: May 13, 2026, 4:10 PM ET

the Board appointed Joseph M. Manko Jr. to join the Board, effective on May 9, 2026.

Departed

Yitzchak Jacobovitz

Director

MYO · MYOMO, INC.

Filed: April 10, 2025, 7:59 PM ET

Also on April 4, 2025, Mr. Yitzchak Jacobovitz, a member of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that he does not intend to stand for reelection at the Annual Meeting.

Departed

Amy Knapp

Director

MYO · MYOMO, INC.

Filed: April 10, 2025, 7:59 PM ET

On April 4, 2025, Ms. Amy Knapp, a member of the Board, the Audit Committee of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders

Earnings & guidance

2026-Q1 EPS reported -$0.07 vs consensus -$0.12 ▲ beat (+39.2%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

10 positive 2 negative 10 neutral

source · MYO on sec.gov